BG Medicine and Copenhagen General Population Study have partnered to discover and validate cardiovascular biomarkers including those predictive of rupture of atherosclerotic plaque and myocardial infarction. The planned research, which will be conducted as part of BG Medicine’s High Risk Plaque (HRP) Initiative, will apply the company’s proteomic and metabolomic discovery platform capabilities.
The HRP Initiative is an industry alliance that aims to discover and develop improved techniques for identifying individuals at risk for heart attacks and the advancement of methods to monitor cardiac disease progression and response to treatment. The HRP Initiative expects to dedicate a total of $30 million in funding toward this research over four years.
The work is expected to commence in March on samples obtained from various Copenhagen cohort studies including the Copenhagen City Heart Study and the ongoing Copenhagen General Population Study and will be conducted in multiple phases.